Music |
Video |
Movies |
Chart |
Show |
FDA Approval of Ribociclib for Metastatic Breast Cancer (OncLive) View |
FDA Approves Kisqali / Ribociclib for Early High-Risk Breast Cancer ESMO 2024 (OncologyTube) View |
FDA Approved For Metastatic Breast Cancer (KTNV Channel 13 Las Vegas) View |
FDA Approves Ribociclib (Kisqali) for Stage 2-3 HR+/HER2- Breast Cancer at Higher Risk of Recurrence (Eleonora Teplinsky) View |
SABCS Snippets: The US FDA Approval of Ribociclib (San Antonio Breast Cancer Symposium) View |
Case 2: CDK4/6 Inhibitors in ER+ Breast Cancer (Targeted Oncology) View |
Expert Perspectives: CDK 4/6 Inhibitors for ER+ Breast Cancer: Emerging Data and Future Implications (HMP Education) View |
Researcher comment: Ribociclib efficacy for visceral metastases | Denise Yardley (Medicine Matters oncology) View |
Study of Ribociclib and PDR001 in HR+ Metastatic Breast Cancer (Dana-Farber Cancer Institute) View |
Ribociclib for HR+ Advanced Breast Cancer (OncLive) View |